About EMFRET Analytics &
Emfret Analytics GmbH & Co. KG is a privately held German biotech company dedicated to the development of antibodies against platelet receptors for research, diagnostic and therapeutic purposes. Founded in 2002, the company has a close and long-standing collaboration with the University Medical Center Würzburg, a leading international center for basic and translational platelet research. This partnership forms the scientific basis for the development of novel research tools and the translation of new insights into platelet biology into innovative therapeutic strategies. Emfret focuses on disease areas that are currently poorly treatable, including stroke, acute lung injury and selected autoimmune diseases. The strategic partnership with Boehringer Ingelheim on the company's first clinical development candidate underscores the potential of a novel class of antibody-based therapeutics designed to precisely modulate pathogenic platelet activity while preserving essential hemostatic function.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Advertisement
